BRH Medical Receives Patents in Both the USA and in China for Its Innovative Wound Healing Therapy
JERUSALEM, Nov. 8, 2016 -- (Healthcare Sales & Marketing Network) -- BRH Medical announced today that the USA and China issued patents for its innovative wound healing system for the treatment of Diabetic Leg Wounds, Venous Leg Ulcers, and Pressure Ulcers... Devices, Wound Care BRH Medical (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2016 Category: Pharmaceuticals Source Type: news
E-Qure wins FDA nod for bio-electrical signal wound therapy
Chronic wound treatment device developer E-Qure said today it won FDA investigational device exemption approval to conduct a clinical trial of its novel Bio-Electrical Signal Therapy device.
The New York-based company said its Bio-electrical Signal Therapy device is designed for non-invasively treating hard-to-heal chronic wounds, including pressure ulcers, diabetic foot ulcers, venous stasis ulcers and other hard to heal ulcers.
A U.S. trial of the device is slated to enroll 90 patients, with a required safety report set to be delivered after initiating the 1st 10 patients to protect from any severe safety issues. The tri...
Source: Mass Device - November 2, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Wound Care E-Qure Source Type: news
Mayo Clinic Minute: 5 steps to diabetic foot care
According to the Centers for Disease Control and Prevention, more than 29 million people in the U.S. have diabetes. Two major complications of the disease are nerve damage and poor blood circulation. These problems make the feet vulnerable to skin sores (ulcers) that can worsen quickly and are difficult to treat.?The good news is that [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 31, 2016 Category: Databases & Libraries Source Type: news
Nearly 50% Reduction in Diabetic Foot Ulcers With Stem Cells Nearly 50% Reduction in Diabetic Foot Ulcers With Stem Cells
Injection of autologous mesenchymal stem cells into diabetic foot ulcers that did not respond to standard of care and offloading resulted in a 50% reduction in ulcer size at 6 weeks in a pilot study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 29, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Celiac disease: 5 things parents need to know
Dr. Dascha Weir, associate director, Boston Children’s Celiac Disease Program
It may be difficult for parents to hear that their child has a chronic illness. When the diagnosis is celiac disease (CD), an autoimmune disorder caused by an intolerance to gluten, there is good news. CD is treatable by changes in diet.
How it works: When food enters the stomach, it’s broken down into tiny digestible particles, which then travel through the small intestine. The small intestine is lined with villi — tiny finger-like projections that absorb nutrients from the food passing through.
In celiac disease, gluten, which is a pro...
Source: Thrive, Children's Hospital Boston - September 28, 2016 Category: Pediatrics Authors: Maureen McCarthy Tags: Diseases & Conditions celiac disease Dr. Dascha Weir gluten intolerance Source Type: news
Fungi contribute to delayed healing of chronic wounds
Fungal communities found in chronic wounds can form mixed bacterial-fungal biofilms and can be associated with poor outcomes and longer healing times, researchers have discovered. Their report is the first deep characterization of the fungi found in diabetic foot ulcers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 6, 2016 Category: Science Source Type: news
Derma Sciences, Organogenesis tout Medicare reimbursement win
Updated to include more information, commentary from Organogenesis.
Medicare administrative contractor National Government Services has retired previous coverage policies on cellular and tissue-based products, effective September 1st.
The change will allow new coverages and reimbursement through Medicare for such products based on FDA labeling and packaging.
Derma Sciences (NSDQ:DSCI and Organogenesis have said the changes will allow for their products to receive coverage and reimbursement for individuals covered under NGS.
Approximately 24 million Medicare Part B beneficiaries are covered by NGS, and with the change ...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news
Derma Sciences touts Medicare reimbursement win
Derma Sciences (NSDQ:DSCI) said yesterday that Medicare Administrative Contractor National Government Services will now consider the company’s Amnioexcel amniotic allograft membrane for coverage.
The change comes as NGS, which serves states in the Northeast and Midwest, sets to retire its local coverage determination for cellular or tissue based products as of September 1st.
The change will allow Derma Sciences’ Amnioexcel to be considered with appropriate documentation of medical necessity as a second-line therapy, following standard wound care treatment.
“We are very pleased with NGS’ decision to...
Source: Mass Device - August 25, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Medicare Regenerative Medicine Derma Sciences Inc. Source Type: news
5 Things You Don't Know About A Dentist
A dentist is simply a doctor in charge of your oral hygiene. So, let me ask you a question:
How many times have you visited a dentist this year?
Alright, you don't have to tell me your answer. Most people don't visit a dentist until they have severe problems in their oral area.
I am also part of this group even if I don't want to admit it. This is because most people are unaware of the importance and usefulness of a dentist. It is recommended that you visit a dentist at least twice in a year to keep your gums and teeth healthy.
Dental visits are supposed to start at the age of 8 years when the permanent teeth are repl...
Source: Healthy Living - The Huffington Post - August 22, 2016 Category: Consumer Health News Source Type: news
Sanuwave files for de novo FDA nod for DermaPace wound care device
Sanuwave Health (OTC:SNWV) said last Thursday it filed a de novo petition with the FDA as it seeks approval for its DermaPace system designed for treating diabetic foot ulcers.
Sanuwave said it expects to hear a response from the FDA within 120 days, and is hopeful that evidence from over 336 patients across 2 trials are enough to “quantify the safety and effectiveness of the non-invasive procedures with the DermaPace system.”
“We are confident that the compelling clinical outcomes demonstrated in this rigorous double-blinded, sham controlled clinical trial provide credible, unbiased evidence that the ...
Source: Mass Device - August 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Diabetes Food & Drug Administration (FDA) SANUWAVE Health Inc. Source Type: news
Derma Sciences closes $80m deal for BioD
Derma Sciences (NSDQ:DSCI) said yesterday that it closed its acquisition of regenerative allograft maker BioD in a deal worth up to $78 million, including milestones and earn-outs.
Princeton, N.J.-based Derma Sciences said it paid $21.3 million up front in a mix of cash and stock; meeting regulatory milestones could mean another $30 million, and the transaction included $26.5 million in earn-outs pegged to net sales growth. The deal, announced July 28, closed August 5, the company said in a regulatory filing.
BioD makes a line of allograft products derived from human placental tissue, including treatments designed fo...
Source: Mass Device - August 12, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Regenerative Medicine Wound Care BioD Derma Sciences Inc. Source Type: news
Covidien spinout Mallinckrodt to acquire Stratatech
Mallinckrodt plc (NYSE: MNK) said today that it agreed to acquire Stratatech and its StrataGraft artificial skin graft technology for an undisclosed amount.
Mallinckrodt, the pharmaceuticals business spun out of Covidien in 2013, said the deal also includes Stratatech’s development program for genetically enhanced skin. The acquisition is expected to close before the end of the year, the Dublin-based company said.
StrataGraft, which is in a Phase III trial for treating deep, partial-thickness burns and a 2nd, Phase II trial for treating severe, full-thickness burns, is a cell-based living tissue designed to mim...
Source: Mass Device - August 11, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Regenerative Medicine Wall Street Beat Wound Care Covidien Mallinckrodt Stratatech Corp. Source Type: news
First report on efficient reprogramming of diabetic foot ulcer cells to create therapeutic stem cell
(Mary Ann Liebert, Inc./Genetic Engineering News) The potential to use a patient's own cells to treat non-healing chronic wounds -- a serious complication of diabetes -- took an important step forward as researchers successfully reprogrammed skin cells taken from diabetic foot ulcers to form induced pluripotent stem cells. The reprogramming technique was similar in efficiency to the results achieved using healthy foot skin from non-diabetic patients, as described in the study published in Cellular Reprogramming. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 10, 2016 Category: Global & Universal Source Type: news
Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers
These cases highlight the use and efficacy of micronized dehydrated human amnion/chorion membrane allografts in patients with diabetic foot ulcers.Wounds (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Cancer-fighting therapy shows promise as treatment to speed up wound healing
A type of targeted therapy that has shown promising results treating advanced melanoma could also be used to help speed up how the skin repairs itself from injury, UCLA researchers have found, providing a potential new way to accelerate healing of acute and chronic wounds.
In the United States alone, chronic wounds affect more than 6.5 million people and an estimated $50 billion is spent annually treating these conditions. Many areas of medicine — from improving recovery times after surgery to reducing skin-related secondary effects of cancer treatments and other diseases — can benefit from speeding up the skin’s hea...
Source: UCLA Newsroom: Health Sciences - August 1, 2016 Category: Universities & Medical Training Source Type: news
